MedTrace Logo

Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

NCT00464282 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2007-04-23

No results posted yet for this study

Summary

Objective: L-\[3-18F\]-α-methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated.

Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

  • Gunma University

    lead OTHER

Principal Investigators

  • kyoichi kaira, MD · Gunma Unversity Graduate School of Medicine

Eligibility

Min Age
8 Months
Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00464282 on ClinicalTrials.gov